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Electronic prescribing has benefited from computerised clinical decision support systems 
(CDSSs) however no published studies have evaluated the potential for a CDSS to support 
General Practitioners (GPs) in prescribing specialist drugs.  
 
Aim 
To identify potential weaknesses and errors in the existing process of prescribing specialist 
drugs that could be addressed in the development of a CDSS.  
 
Design and Setting 
Semi-structured interviews with key informants followed by an observational study involving 
GPs in the UK. 
 
Methods 
Twelve key informants were interviewed to investigate the use of CDSS in the UK. Nine GPs 
were observed while performing case scenarios depicting requests from hospitals or patients 
to prescribe a specialist drug. Activity diagrams, hierarchical task analysis (HTA) and 




The current process of prescribing specialist drugs by GPs is prone to error. Errors of omission 
due to lack of information were the most common errors, which could potentially result in a 
GP prescribing a specialist drug that should only be prescribed in hospitals or prescribing a 
specialist drug without reference to a shared care protocol. Half of all possible errors in the 
prescribing process had a high probability of occurrence. 
 
Conclusion 
A CDSS supporting GPs during the process of prescribing specialist drugs is needed. This 
could, firstly support the decision making of whether or not to undertake prescribing, and 
secondly provide drug specific parameters linked to shared care protocols, which could reduce 
errors identified and increase patient safety. 
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HOW THIS FITS IN? 
In this study, software engineering and human factors methodologies were used to identify 
and analyse the GPs’ current workflow and tasks. Better use of information technology and 
CDSS provide a solution to the current risks associated with prescribing specialist drugs, 




In the UK, initiatives such as practice-based commissioning have encouraged the 
development of GPs with special interests to deliver specialist services in the community.1 The 
introduction of GP commissioning and transfer of the NHS primary care budget to GP 
consortia,2 has been seen as an opportunity to change the arrangements for prescribing 
specialist drugs and providing new services within primary care to avoid patients attending 
hospital clinics.3 Specialist drugs are those which have significant pharmacological complexity 
and/or rarity of use making prescribing in primary care relatively uncommon.4 In 1991, the 
NHS Management Executive outlined core principles and clinical responsibilities associated 
with prescribing at the primary and secondary care interface including the use of protocols to 
support GPs prescribe specialist drug under shared care agreements.1 Local advisory lists 
were made available to support GPs in managing shifts in prescribing from secondary care to 
primary care with medicines grouped as hospital only (red), appropriate for shared care or 
restricted use (amber), and for GP use and initiation (green).5  
 
NHS Prescription Services provides prescribing, financial and drug information to managing 
organisations within the NHS in England. In 2006-07 1.3 million prescriptions for specialist 
drugs were issued by GPs,6 rising to 1.7 million in 2014-15,7 with the most frequently 
prescribed specialist drugs (29.3%) being the immunosuppressant drugs ciclosporin, 
mycophenolate, sirolimus and tacrolimus. Between 2005 and 2010 these four drugs were 
involved in 1103 reported safety incidents with 282 (25.5%) directly related to prescribing, with 
11 occurring in primary care (National Patient Safety Agency, personal communication, 2 
March 2011)From April 2013 changes in NHS commissioning arrangements for specialist 
drugs and services have allowed hospitals to repatriate the prescribing of immunosuppressant 
drugs from primary care to secondary care.8 
 
The specialist drugs list maintained by NHS Prescription Services is not exhaustive and does 
not specify which drugs should be classed as red or amber. This responsibility rests with local 
organisations such as area prescribing committees which can lead to regional variation in 
which specialist drugs are recommended for use only in secondary care or those suitable to 
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be prescribed by GPs under shared care arrangements (in the form of local advisory lists). In 
2014-15 41.89% of prescriptions for specialist drugs issued by GPs in England were classified 
as red that is hospital only based on the traffic light classification used across North West 
London.9 
 
Shared care protocols are developed and approved by local area prescribing commitees such 
as the Midlands Therapeutic Advisory Committee.10 Shared care protocols must be patient 
specific and clarify individual roles and responsibilities, medicine details, patient monitoring 
and circumstances where treatment should be modified or stopped.1 One UK survey has 
reported on the production of 321 shared care protocols that have described 99 different drugs 
or treatments.11 A range of factors influence GP decision making in prescribing specialist drugs 
including shared care arrangements and the influence of local advisory lists.12 GP 
dissatisfaction with arrangements for prescribing specialist drugs,13 and a lack of GP 
involvement in the development of shared care protocols has been reported.11,14 Barriers to 
GP acceptance of shared care protocols have included cost shifting,11,13 training,15 staffing and 
time constraints.16 Shared care protocols have been described as variable in standard, lacking 
formal evaluation, distributed erratically and with unclear benefits to patients.11 Suggested 
improvements to shared care protocols have included joint agreement between primary care 
and secondary care,15 a clearer definition of roles and responsibilities and to dissect barriers 
such as risk management and clinical competence.16 One potential solution lies in 
computerised clinical decision support systems (CDSSs).  
 
In the last 30 years CDSSs have emerged to aid diagnosis, disease management, 
calculations, and more recently supporting electronic prescribing via alerts on drug 
interactions, allergies and contraindications.17 Systematic reviews of controlled trials of CDSSs 
within primary care settings demonstrated largely positive effects linked to adherence to 
clinical guidelines,18,19 improved prescribing,20 clinician performance,21 and drug dosing and 
therapeutic response.22 However limitations include a lack of evidence in improving safety 
measured by medical errors or adverse events,23 and in patient outcomes.24,25 Poor usability 
has been cited as a core barrier to CDSS adoption, with system designers encouraged to 
apply common standards based on human-computer interaction methods and user-centred 
design.26  
In the UK, commercial CDSS that supports cost effective prescribing is widely available to 
GPs.27,28 In a recent development CDSS has become available to support GPs in 
implementing medicines optimisation.29 Such systems are able to provide locally authored 
messaging platforms to provide drug information and safety alerts to prescribers including 
links to local advisory lists known as traffic light classifications and shared care protocols. 
5 | P a g e  
 
However, in a recent review,30 the impact of one of these systems,28 has been described as 
limited compared to other existing cost effective prescribing initiatives with drawbacks 
including alert content, and a lack of GP control. No published study has evaluated the 
potential for a CDSS to support GPs prescribe specialist drugs. In the current study software 
engineering and human factors methods were used to identify a potential operating model for 




A review of the published literature of CDSSs in the UK identified four stakeholder groups who 
would provide insight into the requirements of a potential CDSS that could support GPs during 
the process of prescribing specialist drugs. An exploratory study was initially undertaken using 
face-to-face interviews with 12 key informants which were all conducted by the lead trained 
research  pharmacist.The key informants were GPs (n = 2), NHS IT managers (n = 2), 
secondary care clinicians (n = 4) and representatives from the CDSS industry / GP clinical 
system suppliers (n = 4). Secondary care clinicians with a specialist knowledge of drugs an 
immunosuppression in renal transplantation were invited to participate. UK-based commercial 
CDSS and GP clinical system suppliers were approached while London-based IT managers 
and GPs were invited. These interviews were used to gain an understanding of current usage 
and characteristics of CDSSs available within primary care and to explore the feasibility of 
incorporating a CDSS to support GPs in the prescribing of specialist drugs. Interview 
schedules were designed for each stakeholder group and used as a topic guide. During each 
interview emerging themes were used to formulate further questions. Interviews were 
recorded, transcribed verbatim and analysed using framework analysis,31 supported by NVivo 
(Version 10). The resulting data was reviewed by members of the research team and analysed 
for emerging key themes across the interviews. 
 
In order to further understand the actual needs and requirements of GPs as end users of a 
potential CDSS, an observational study with GPs was conducted. In total nine GPs who were 
users of the three major UK GP clinical systems (EMIS, Vision and SystmOne) were 
purposively32 selected to participate. The selection took into account the results from the key 
informant interviews and factors such as GP availability, willingness to participate and 
demographic characteristics. Six of the GPs were partners whilst three were salaried GPs. 
The GPs qualified between 2001 and 2013. All of the GPs described themselves as having 
either a medium or high IT aptitude. In this observational study the lead researcher discussed 
and observed the participants perform pre-defined case studies and took written notes on 
performed tasks and workflows. A research guide was designed to include specific pre-
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determined questions about computer use including CDSSs both during and outside patient 
consultation with emerging themes used to formulate further questions. Case scenarios were 
developed from the results of the key informant interviews with particular emphasis on the 
use, quality and availability of shared care protocols. The case scenarios were observed and 
discussed with each GP depicting situations where patients  presented prescriptions for 
specialist drugs (for example tacrolimus) or these were requested by the hospital, identifying 
the steps taken by each GP to accept or decline prescribing.   
 
Data Analysis 
Data from the observations and discussions were used to develop activity diagrams 
representing how GPs conducted their work, used their computers both during and outside 
patient consultation, and how they dealt with the specialist drug prescribing case scenarios. 
Activity diagrams are often organised as swim lanes to identify who or what is responsible for 
a specific task or activity,33 and have been used to model workflow patterns involved in 
prescription writing and management within primary care settings.34 A hierarchical task 
analysis (HTA) was performed to describe in detail the process GPs used to prescribe 
specialist drugs. HTA models tasks as hierarchies of goals and sub-goals, with plans showing 
how sub-goals should be undertaken.35 Error analysis based on SHERPA36 was applied to the 
HTA sub-tasks identifying possible errors, consequence, recovery, probability of occurrence 




The primary themes that emerged from the exploratory interviews were safety, IT systems and 
costs, which are shown in Box 1 with secondary themes and emerging key criteria. In total 25 
CDSSs were identified of which nine were active systems (provide patient-specific advice), 
and 16 passive (clinicians need to request the information, not patient-specific). The CDSSs 
supported a wide range of activities including prescribing, drug information and disease 
management. All of the GP clinical systems provided active CDSSs to support prescribing via 
drug alerts or warnings and reminders or prompts to support the Quality and Outcomes 
Framework (QOF) component of the national General Medical Services (GMS) contract. In 
terms of specialist drugs and shared care protocols, mixed experiences were described by the 
GPs and secondary care clinicians, with specific concerns from a GP perspective in relation 
to safety, clinical responsibility to prescribe, and in the availability and quality of shared care 
protocols (Box 2). The concept of developing a CDSS to support GPs prescribe specialist 
drugs was acknowledged as beneficial by all 12 key informants. Enablers and barriers to 
CDSS development were identified including a number of potential operating and funding 
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models (see Box 2). Key enablers included multi-user access, active alerting, ease of use, 
joint development and implementation, patient involvement, data quality and functionality, and 
the use of existing systems and frameworks. Key barriers included security and regulation, 
implementation, integration and data quality and addressing the needs of end users.  
 
Activity aiagram and hierarchical task analysis 
GPs described their actions to the case scenarios, deciding whether or not to accept clinical 
responsibility for prescribing a specialist drug. Figure 1 displays the activity diagram 
representing their decision making process. The GPs described limited functionality within 
each GP clinical system to support the prescribing of specialist drugs. All GPs highlighted the 
importance of adding simple alerts/reminders to the patient’s electronic health record (EHR) 
to indicate that the patient was treated with a specialist drug or that a shared care protocol 
should be followed. Additional needs included restricting drug quantities and creating tasks 
such as recall to ensure patients were seen on a regular basis. Where shared care protocols 
were available, all GPs reported they should be scanned and added to the patient’s EHR. An 
additional problem identified was the reliability of administrative staff to scan letters or 
communications from hospitals. Although the GPs found the use of the clinical systems quick 
and simple, navigating the systems to locate a shared care protocol was not straightforward 
(for example if the scanned letters were not filed by speciality they were difficult to locate). 
HTA was applied to the actual task of prescribing specialist drugs and is shown in Box 3. Key 
steps undertaken were to open the patient’s EHR and to familiarise themselves with patient’s 
clinical history before reviewing the request to prescribe a specialist drug. GPs checked if the 
specialist drug was ‘hospital only’ or whether it could be prescribed by using a shared care 
protocol. These checks were made by locating and referring to a traffic light classification of 
specialist drugs. Although CDSS providing support at the point of prescribing was available 
e.g. ScriptSwitch®, none of the GPs referred to this specific functionality during the decision 
making process. 
 
Errors involved in prescribing specialist drugs 
The SHERPA analysis demonstrated that although the specific task of prescribing was 
relatively simple in terms of the number of steps required to complete the task, the potential 
for error was considerable (Boxes 4 and 5). The potential errors that could occur were either 
cited by the individual GP (GP1 to GP9) or identified by the research team  during data 
analysis. The underlying problem faced by the GPs was dealing with a paper based 
communication system with secondary care. The risk of prescribing specialist drugs in an 
unsafe manner was increased due to lack of functionality within all the GP clinical systems 
and time constraints particularly where a decision needed to be made during a consultation. 
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To resolve these issues GPs relied on other staff to provide advice and information. In many 
cases the next opportunity to resolve such problems was when a further prescription was 
requested by the patient. The predominant theme that emerged from the SHERPA analysis 
was the high frequency of error mode R1 (“Information not obtained”) because information 
required by the GP was not readily available. The potential adverse outcome was that a GP 
could inadvertently prescribe a specialist drug classified as hospital only, or prescribe one 
without reference to an appropriate shared care protocol. In addition, in 11 of the 20 task steps 
an error rated as a high probability of occurrence could occur. The fundamental problems 
described by the GPs related to lack of awareness or availability of either the traffic light list or 
shared care protocols. In addition, where shared care protocols were required, a major 
obstacle was locating them in either a paper or electronic format, particularly during patient 
consultations.  
 
It was evident throughout the whole process that GP clinical systems and CDSSs were not 
able to provide full solutions to the problems described by the GPs. One remedial solution was 
to manually add simple alerts or reminders to the patients’ EHR. These alerts allowed free text 
to be added to a pop up box informing each user of key messages related to prescribing of 
specialist drugs, for example checking the shared care protocol or requirements for regular 
blood tests. Other interventions described were manual tasks to contact and liaise with a range 
of individuals such as other GPs, primary care pharmacists and clinical teams within 
secondary care. Application of both HTA and SHERPA identified a potential operating model 
for a CDSS to support GPs in prescribing specialist drugs. Box 6 describes a HTA of this 
proposed model demonstrating how GPs could potentially safely prescribe a specialist drug 




Previous studies have identified concerns from GPs in prescribing specialist drugs and in the 
use of shared care protocols,11-13 Difficulties have included lack of awareness or access to 
either local traffic light classification lists or shared care protocols.11 Furthermore, CDSSs have 
been reported to appear too late during patient consultations, by which time GPs had already 
made a decision around treatment options.37 In the current study it was identified that the lack 
of specific functionality within GP clinical systems (EMIS, Vision, SystmOne) including CDSSs, 
adversely affected the GPs’ ability to resolve problems associated with prescribing of specialist 
drugs. To the authors’ knowledge this is the first study, to perform a detailed analysis of the 
tasks and potential errors (HTA and SHERPA) during the prescribing process in the three 
major GP clinical systems available in the UK. This detailed analysis enabled the identification 
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of specific weaknesses and potential errors with current systems that have not been previously 
identified, and to propose possible solutions in the form of a potential operating model for a 
CDSS to support GPs in prescribing specialist drugs.  
 
Strengths and Limitations 
The strength in thiswork resides in its use of human factors methods (HTA and SHERPA) for 
analysing the GPs tasks and workflows in prescribing specialist drugs. Using human factors 
techniques and risk assessment methods are encouraged for designing healthcare 
interventions.38,39 Nevertheless, this is the first study that has analysed the prescribing of 
specialist drugs by GPs using these methods. Participants used the three major GP clinical 
systems available in the UK. This ensures that the findings are relevant to the majority of GP 
practices. However, the recruitment process of the participants was not optimal as two of the 
GPs (GP1, GP2) participated in both the exploratory study and the main study, whilst GP3 
was involved in the piloting of the exploratory study and also participated in the main study. 
All of the GPs worked within a single clinical commissioning group (CCG), were purposively 
selected and were known to the lead researcher which may have introduced bias. All of the 
GPs described themselves as having either good or high IT aptitude, and this may have 
introduced bias linked to competencies in the use of computers, GP clinical systems and 
CDSS. Therefore less computer literate participants could have found the prescribing process 
even more challenging. A limitation of this research is the focus of the HTA on the process of 
prescribing at the exclusion of other tasks GPs routinely perform, e.g. history taking or patient 
examination. Future work to develop a fully functional CDSS will need to consider how 
prescribing interacts with other consultation tasks. However, this approach is common during 
the early stages of technology development, before more detailed process of interface design 
are undertaken. Furthermore, although HTA was chosen as the preferred research method in 
this study, the results from the SHERPA analysis identified that further exploration of the 
decision making processes used by GPs is required. This could be undertaken by adopting a 
cognitive approach to task analysis to inform further research in this area. It is also common 
that repeat prescribing and tasks relating to hospital correspondence are undertaken 
separately from the patient consultation. 
 
Comparison with Existing Literature 
Although healthcare has increased the awareness of retrospective safety assessment 
techniques such as root cause analysis, the use of predictive safety assessment techniques 
(such as SHERPA, Failure Modes and Effect Analysis) is limited and there is a need to adopt 
more proactive and rigorous approaches.40,41 This work is novel as no previous study has 
applied HTA and SHERPA to inform a CDSS for prescribing specialist drugs. Previously 
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reported use of HTA with or without SHERPA in the UK has been primarily limited to the study 
of endoscopic surgery,42 diagnosis,43 drug administration,44 and anaesthesia use.46 
 
Implications for research  
The results from this study have highlighted that despite the availability of CDSSs and other 
functionality within GP clinical systems, safety concerns remain with the use of specialist drugs 
prescribed by GPs in primary care. Designing a CDSS that considers the needs of GPs, their 
current workflow, and their decision making process has the potential to both facilitate the 
prescribing of specialist drugs and decrease the associated risks with prescribing errors. 
Designing and evaluating with GPs a CDSS prototype, based on the authors’ operating model 
could be a meaningful step in improving the current prescribing process. In addition, further 
research could investigate how GP clinical systems and community pharmacy systems could 
incorporate active hard stops to alert users when hospital only drugs are prescribed. 
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Box 1. Summary of primary and secondary themes from key informant interviews 
Primary 
Theme 









 Communication: problems specifically between 
primary care and secondary care (interface) 
 Clinical responsibility: for GPs when prescribing 
specialist drugs 
 Monitoring of patients receiving specialist drugs 
 Experiences of specialist drugs (adverse 
experiences such as drug interactions, generic 
prescribing, repatriation of prescribing to 
secondary care) 





features of IT 
systems (primary 
care) 
General usage of computers in general practice and 
key characteristics of IT systems 
 Regulation (current NHS management systems, 
GP system vendors and shifting to hosted 
systems) 
 Data quality (read coding, accuracy, 
accreditation) 
 Integration of systems 
 Implementation of systems 
 CDSS and experience in general practice 
(current profiles, usage and characteristics) 
 Current and future developments in CDSS 
 CDSS and specialist drugs (views and attitudes , 
enablers, barriers) 
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Cost Drug costs, service 




 Prescribing budgets (primary care) 
 NHS service costs and use of homecare 
 GP System of Choice (GPSOC) Framework 
(License fees), CDSS funding streams 
 CDSS and specialist drugs: Funding models  
 
 
Box 2. Key informants’ views on the use of specialist drugs, shared care protocols and 
the concept of developing a clinical decisions support system to support GPs prescribe 
specialist drugs 
Specialist drugs and shared care protocols 
 
“I never had any awareness of shared care protocols, I think they are universally pretty 
useless and I think they are a significant area of potential danger.” (GP 1)  
 
“I think it’s something that we frequently get letters from the hospital consultants......you 
know or this is the drug they are taking, it’s not made clear to us if we’re expected to take 
on prescribing, it’s not made clear to us if there is a shared care protocol in place, it’s 
certainly not clear that they have any idea if there are shared care protocols in place.”  
(GP 1) 
 
“My normal first response is no we won’t take this on until we get the protocol and when it 
is sent it is not written in my perspective......in the sense that it’s often written from how it’s 
initiated......not terribly helpful or easy to use.” (GP 2) 
 
“I have written quite a lot of them (shared care protocols)......usually renal drugs......once I 
have written it I send it to our formulary pharmacist......and then she goes to meetings with 
the local PCTs......rather than the individual PCTs now we deal with the sector.” (Secondary 
Care Clinician 2) 
 
“I think drug interactions are one of the major headaches that we have with 
immunosuppressant drugs, you know mainly penicillin allergic patients come in with a fever 
and a chest infection and they get clarithromycin and then the next thing you know their 
tacrolimus levels have doubled.” (Secondary Care Clinician 3) 
 
“There is a huge variation in bioequivalence, we had one patient who had the wrong brand 
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of tacrolimus and came in and rejected due to lower levels of tacrolimus……we had another 
patient who came in who had a recurrence of herpes zoster because she had received a 









Box 2. Key informants’ views on the use of specialist drugs, shared care protocols and 
the concept of developing a clinical decisions support system to support GPs prescribe 
specialist drugs (cont.) 
 
Developing a CDSS to support GPs prescribe specialist drugs 
 
“I think the priority for me would be to have......you know if for example if the shared care 
protocol is presented to me at the time of prescribing, at the point of prescribing, it’s no 
good having some dim and distant website, somewhere having to trawl though for every 
drug, every indication, that is useless.” (GP 1)  
 
“It has to be intuitive......it has to be minimally intrusive unless where it needs to be intrusive, 
so it shouldn’t take me 15 minutes for me to do something where previously I would do in 
2 minutes.” (CDSS industry / GP clinical system supplier representative 4) 
 
“The barriers would be there from the big players the clinical applications out there in the 
practices, EMIS, Vision, SystmOne......the barriers would be for them for allowing these 
new guys, this company coming along with this product to talk to them and say yes we can 
make it work with our product.”(NHS IT Manager 1) 
 
“So then it can be an extension of the system the GP already has......which depending on 
the exact complexity of what you want it is not going to be that expensive......if you wanted 
a stand - alone system that was used by the GP for these drugs and by hospital clinicians 
that initiated the drug it becomes a different cost model altogether, particularly if the 
hospital records are still paper.” (CDSS industry / GP clinical system supplier 
representative 2) 
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“And there are substantive costs, not just development but on-going maintenance of the 
product and the NHS has not always been able to do that particularly well......and I think it 
is very telling......that the NHS has not chosen to be one of the GP Systems of Choice.” 
(CDSS industry / GP clinical system supplier representative 4 ) 
 
“In order for it be fair to a GP you would have to build in a very high level of supervision in 
terms of checking......basically calling the patient’s back to have their renal function 
checked and their levels checked after dose changes......you are basically asking the GP 
to run a transplant clinic and I think that would be a lot to ask......clearly transplants are 
about life sustaining organs......livers, hearts and lungs if you get that wrong then it’s good 
night Vienna.” (Secondary Care Clinician 4)  
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Figure 1. Activity diagram representing GPs’ decision making in managing requests 
to prescribe specialist drugs 
CCG = clinical commissioning group. CDSS = clinical decision support system. EHR = 






 Prescribing template 
 Drug selection: drug name, dose, quantity, 
treatment duration  
 Use mouse and or keyboard to enter text or to 
select from the drop down menus or fields 
 CDSS: Active and Passive  
 Repeat Prescribing Management Fields: Number 
of authorised repeats, review date, batch repeats 
Internal to the patients’ 
EHR 
 
CDSS (Active): Allergies, 
drug interactions, warnings, 
e.g. ScriptSwitch® 
CDSS (Passive): Prompts, 
icons (e.g. EMIS Mentor®) 
Pathology results, other 
biochemical or physical 
markers 
Hospital communications  
External to the patients’ 
EHR 
 
CDSS (passive) e.g. clinical 
guidelines, Patient.co.uk 
Use of the internet 
Books, journals, paper notes  
Specialist Drugs: Key 
Issues for GP  
 
Is this a hospital only drug or 
a drug that can be prescribed 
under a shared care 
protocol?  
 
Checking / locating the local 
CCG traffic light list 
 
Checking / locating the 
shared care protocol  
 
Clinical responsibility and 
agreeing to prescribe the 
specialist drug: YES or NO  
 
Locating a shared care protocol / traffic light list  
 May be available as a scanned document within the 
patient EHR; how is it located, is it easy to 
navigate the GP clinical system? 
 May be available electronically via a web-based 
resource (e.g. CCG extranet); how is it located; 
external to the patient EHR 
 If unable to locate to contact hospital (e.g. via 
telephone or by letter) 
 If unable to locate contact the CCG pharmaceutical 
adviser (e.g. via telephone or e-mail) 
 Discuss with GP colleagues  e.g. clinical meetings 
 Identifying drug specific monitoring and prescribing 
advice (passive CDSS e.g. CKS) 
 Contact community pharmacist for advice 
 Consider other actions to include adding manual 
alerts to warn clinicians regarding the need for a 
shared care protocol or specific criteria e.g. blood 
tests, drug interactions 
 Patient recall, limit prescription quantity 
 Consider the above in relation to opportunities to 






GP agrees to prescribe the specialist drug either as acute or 
repeat prescription. If GP does NOT agree to inform patient 
GP 
GP issues prescription and to 
record any additional relevant 
details in patient’s EHR 
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Box 3. Hierarchical task analysis of the prescribing of specialist drugs by GPs  
(Current tasks) 
 
Prescribing a specialist drug 
PLAN 0: Either during or outside a patient consultation do 1, 2 and 3 in order. 
1. Open patient’s electronic health record 
2. Get familiar with patient’s clinical history 
3. Review a request to prescribe a specialist drug 
PLAN 3: 
Do 3.1 to 3.8 in order according to instructions 
3.1 Check traffic light list if drug is “hospital only”. If “Yes” go to 3.8. If  
       “No” go to 3.2 
3.2 Check if drug can be prescribed under a shared care protocol. If   
      “Yes” go to 3.3, if “No” go to 3.8 
3.3 Locate the shared protocol 
3.4 Read shared care protocol. If agree to accept clinical   
      responsibility, go to 3.5, if decline go to 3.7 
3.5 Accept clinical responsibility for prescribing the specialist drug 
3.6 Prescribe specialist drug 
3.7 Decline clinical responsibility for prescribing the specialist drug  
      go to 3.8 
3.8 DO NOT prescribe drug. Refer back to the hospital clinic and  
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Box 4. SHERPA error modes 
 
Error Type Code Error mode 
 
Action errors A1 Operation too long/short  
 
 A2 Operation mistimed  
 
  Operation in wrong direction 
  
 A4 Operation too little/much 
  
 A5 Misalign 
  
 A6 Right operation on wrong object  
 
 A7 Wrong operation on right object  
 
 A8 Operation omitted  
 
 A9 Operation incomplete  
 
 A10 Wrong operation on wrong object 
 
Checking errors C1 Check omitted  
 
 C2 Check incomplete  
 
 C3 Right check on wrong object  
 
 C4 Wrong check on right object  
 
 C5 Check mistimed  
 
 C6 Wrong check on wrong object  
 
Retrieval errors R1 Information not obtained  
 
 R2 Wrong information obtained  
 
 R3 Information retrieval incomplete  
 
Communication errors I1 Information not communicated  
 
 I2 Wrong information communicated  
 
 I3 Information communication incomplete  
 
Selection errors S1 Selection omitted  
 
 S2 Wrong selection made 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
3.1 To check if the 
specialist drug is a 
“hospital only” drug. 
C1 Failure by GP to check 
the traffic light list (GP1, 
GP3, GP4, GP7) 
A hospital only 
specialist drug is 













that a hospital 






Screen alert when prescribing 
  
Design Solution: The GP clinical system 
to automatically alert the GP that this is a 
hospital only drug, not to prescribe and to 
automatically refer back to the hospital i.e. 
a hard stop.  
 
Design Solution: The GP clinical system 
to enable a search of a drug and see its 
attributes i.e. “hospital only”  
 
Design Solution: The pharmacy computer 
system to automatically alert the 
pharmacist that this is a hospital only drug 
and not to be issued in primary care and to 
refer back to the GP 
 
 R1 Traffic light list is not 
available at the practice 
(paper list) (GP1) 
A hospital only 
specialist drug is 








Screen alert when prescribing (same 
design solutions as above) 
 
Practice to ensure paper list is available to 
all GPs including locums 
 
 R1 Traffic  light list  is 
available at the practice 
(paper list), but is out of 
date 
A hospital only 
specialist drug is 






Low Screen alert when prescribing (same 
design solutions as above) 
 
Practice to ensure updated / current paper 
list is available to all GPs including locums 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error 
mode 
Description Consequence Recovery P Remedial strategy / design solution 
 R1 Traffic light list is available 
at the practice (via local 
extranet) but lack of GP 
awareness (GP1)  
A hospital only 
specialist drug is 









Screen alert when prescribing (same design 




 R1 Traffic  light list is 
available at the practice 
(via local extranet) but 
lack of GP access rights 
(GP1) 
A hospital only 
specialist drug is 








To make a link available to local extranet 
web-page. Practice to ensure all GPs and 
locums have a user name and password 
and an easy way to retrieve them 
 
3.2 To check if a 
shared care protocol 
is required to support 
the prescribing of a 
specialist drug 
C1  Failure by GP to check 
the traffic light list (GP1, 
GP3,GP7) 
A specialist drug 
may be prescribed 
without reference to 








Screen alert when prescribing 
 
Design Solution: The GP clinical system to 
enable a search of a drug and see its 
attributes i.e. a shared care protocol is 
required  
 R1 Traffic  light list  is not 
available at the practice 
(paper list) 
A specialist drug 
may be prescribed 
without reference to 








Screen alert when prescribing 
 
Practice to ensure paper list  is available to 
all GPs including locums 
 R1 Traffic  light list  is 
available at the practice 
(paper list), but is out of 
date 
A specialist drug 
may be prescribed 
without reference to 
the current shared 





Low Screen alert when prescribing 
 
Practice to ensure updated / current paper 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error mode Description Consequence Recovery P Remedial strategy / design solution 
 R1 Traffic  light list is available 
at the practice (via local 
extranet) but lack of GP 
awareness (GP1, GP8) 
 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol.  





Screen alert when prescribing 
 
 R1 Traffic  light list is available 
at the practice (via local 
extranet) but lack of GP 
access rights (GP1, GP8) 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol.  
At next request 
for prescription 
(3.2) 
High To make link available to local extranet web-
page  
 
Practice to ensure all GPs and locums have a 




3.3 To locate the 
shared care protocol to 
support the GP in 
prescribing the 
specialist drug. 
R1 Shared care protocol not 
available to GP (paper copy) 
as not sent by hospital 
clinic. GP unable to contact 
clinic due to time constraints 
(GP1,GP2, GP6, GP7) 
 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
At next request 
for prescription 
(3.3)  
High Screen alert when prescribing 
 
Ensure hospitals send copies of shared care 
protocols to GPs (action for medicines 
management team*) 
 
 R1 Shared care protocol not 
available to GP (paper copy) 
as filed in patient’s paper 
notes and NOT scanned into 
patients’ EHR (GP1) 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
At next request 
for prescription 
(3.3)  
Low Ensure paper copy of shared care protocol is 
scanned into patients’ EHR (for practice staff). 
Need to highlight in practice policy in handling 
communications from hospitals i.e. scanning in 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error mode Description Consequence Recovery P* Remedial strategy / design solution 
 R1 Shared care protocol has 
been scanned into patients’  
EHR, but not easily available 
or difficult to locate (i.e. 
difficulty in navigating the 
clinical system) 
 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol.  







Design solution: The GP clinical system to 
make the protocol easily available and or 
identifiable within the patient’s EHR 
 
Training for GP on the use of the clinical system 
 R1 Shared care protocol is not 
available via the local 
extranet (GP6, GP8) 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
 
At next request 
for prescription 
(3.3) 
High To ensure that the shared care protocol is 
available on local extranet (action for  
medicines management team*) 
 
  
 R1 Shared care protocol is 
available on local extranet 
but  lack of GP awareness  
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
 
At next request 
for prescription 
(3.3) 
High Screen alert when prescribing 
 R1 Shared care protocol is 
available via local extranet 
but lack of GP access rights 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
At next request 
for prescription 
(3.3) 
High To make a link available to local extranet web-
page (will need user name and 
password).Practice to ensure all GPs and 
locums have a user name and password and 
an easy way to retrieve them 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
Task step  Error mode Description Consequence Recovery P Remedial strategy / design solution 
 R1 Shared care protocol is 
available via local extranet 
but out of date 
A specialist drug may 
be prescribed without 
reference to the 
current shared care 
protocol. 
 
At next request 
for prescription 
(3.3) 
Low To ensure that the current shared care 
protocol is available on local extranet (action 
for medicines management team*) 
 
 R1 Lack of GP awareness of 
availability of shared care 
protocols from other external 
web based NHS resources 
(GP1, GP2) 
A specialist drug may 
be prescribed without 
reference to the 
shared care protocol. 
 





Screen alert when prescribing with names of 
external web based NHS resources 
 R1 Lack of GP awareness of 
prescribing support from 
other electronic or manual 
resources (drug specific e.g. 
drug interactions, 
monitoring) (GP1, GP3, 
GP9)  
A specialist drug may 
be prescribed without 
reference to the 




end of surgery 
(3.3) 
 
At next request  
for prescription 
(3.3) 
High Screen alert when prescribing: Checks  to be 
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Box 5. Application of SHERPA to the prescribing of specialist drugs by GPs (cont.) 
 
Task step  Error mode Description Consequence Recovery P* Remedial strategy / design solution 
 R1 GP unaware of local  CCG 
pharmaceutical adviser 
contact details (GP1, GP2, 
GP3, GP4, GP5, GP8, GP9) 
A specialist drug may 
be prescribed without 
reference to the 




end of surgery 
(3.3) 
 





Details of local CCG pharmaceutical adviser to 
be made available either at the GP practice and 
or within the GP clinical system 
 
 
*medicines management team refers to the NHS pharmacist led management framework that supports and advises local NHS commissioning 
groups, GPs, and other stakeholder groups, although actual arrangements may differ locally 
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Box 6. Hierarchical task analysis for prescribing specialist drugs by GPs 
(Potential operating model supported by CDSS) 
 
Prescribing a specialist drug 
PLAN 0: Either during or outside a patient consultation do 1, 2 and 3 in order. 
1. Open patient’s electronic health record 
2. Get familiar with patient’s clinical history 
3. Review a request to prescribe a specialist drug 
PLAN 3: 
Do 3.1 to 3.10 in order and according to instructions 
3.1 Enter the “Management of Specialist Drugs Module” integrated   
       within the EHR 
3.2 Enter drug name and check drug attributes 
3.3 If drug is “hospital only” go to 3.10 
3.4 If drug requires a shared care protocol go to 3.5 
3.5 Module will automatically update fields for monitoring  
      requirements according to the information in the patient’s EHR 
3.6 If data is not available within patient’s EHR, module will  
      automatically prompt action or task, e.g. full blood count 
3.7 Decide whether to accept clinical responsibility for prescribing the  
      Specialist drug. If agree to accept clinical responsibility go to 3.8,  
      if decline go to 3.9 
3.8 Follow the prescribing workflow and issue prescription (consider  
      repeat or acute prescription) 
3.9 Decline clinical responsibility for prescribing the specialist drug go  
      to 3.10 
3.10 Exit module, system will automatically refer to hospital clinic,  
        inform patient. 
3.11 Module will save all recorded information with relevant read  
        codes in the patient’s EHR on exit and automatically update the  
        prescribing authorisation and/or review date. 
3.12 If GP does not enter the “Management of Specialist Drugs  
        Module” and prescribes a “hospital only” drug or prescribes a  
        drug without reference to the shared care protocol, the GP   
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